News

FDA Strengthens Kidney Warnings on Two Diabetes Drugs

Author and Disclosure Information

 

References

The Food and Drug Administration has revised warnings on certain medications for type 2 diabetes mellitus based on recent reports of kidney injury. The warning labels on canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR) now include recommendations on ways to minimize the risk and more information on kidney injury.

“From March 2013, when canagliflozin was approved, to October 2015, FDA received reports of 101 confirmable cases of acute kidney injury, some requiring hospitalization and dialysis, with canagliflozin or dapagliflozin use,” the FDA statement said.

Courtesy Wikimedia Commons/FitzColinGerald/Creative Commons License

The FDA went on to note: “Health care professionals should consider factors that may predispose patients to acute kidney injury prior to starting them on canagliflozin or dapagliflozin. These include decreased blood volume; chronic kidney insufficiency; congestive heart failure; and taking other medications such as diuretics, blood pressure medicines called angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), and nonsteroidal anti-inflammatory drugs (NSAIDs). Assess kidney function prior to starting canagliflozin or dapagliflozin and monitor periodically thereafter. If acute kidney injury occurs, promptly discontinue the drug and treat the kidney impairment.”

Recommended Reading

Study of Twins Quantifies Diabetes, Obesity Link With Psoriasis
Clinician Reviews
FDA Alert: Canagliflozin Use May Be Associated With Toe, Foot Amputations
Clinician Reviews
Sitagliptin Does Not Reduce Liver Fat in NAFLD
Clinician Reviews
Lipoprotein(a) and Cardiovascular Disease
Clinician Reviews
Diabetic Foot Ulcers Linked to Cognitive Decline
Clinician Reviews
Liraglutide Prevents Ketogenesis in Type 1 Diabetes
Clinician Reviews
Starting With Combination Diabetes Therapy Beats Initial Monotherapy
Clinician Reviews
Initial Monotherapy Safe in Type 2 Diabetes but Must Be Abandoned Quickly if Ineffective
Clinician Reviews
Smart Insole System Helped Reduce Reulceration Risk
Clinician Reviews
Comprehensive Diabetic Retinopathy Screening Challenging
Clinician Reviews